These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26989807)

  • 1. New horizons in osteoporosis therapies.
    Harsløf T; Langdahl BL
    Curr Opin Pharmacol; 2016 Jun; 28():38-42. PubMed ID: 26989807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2017 Jan; 13(544-545):88-90. PubMed ID: 28703545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Importance of teriparatide in the treatment of osteoporosis].
    Yamauchi M
    Clin Calcium; 2016 Jun; 26(6):905-13. PubMed ID: 27230847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical approach for anabolic treatment of bone fragility with romosozumab.
    Cianferotti L; Cipriani C; Palermo A; Viapiana O; Zavatta G; Mazziotti G
    J Endocrinol Invest; 2024 Nov; 47(11):2649-2662. PubMed ID: 38789679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future treatments of osteoporosis in men.
    Kaufman JM; Lapauw B; Goemaere S
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):871-84. PubMed ID: 25432358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Bone-Forming Therapies for the Management of Osteoporosis.
    Sølling ASK; Harsløf T; Langdahl B
    Drugs Aging; 2019 Jul; 36(7):625-638. PubMed ID: 31066015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Osteoporosis: Unmet Needs and Emerging Solutions.
    Langdahl BL; Andersen JD
    J Bone Metab; 2018 Aug; 25(3):133-140. PubMed ID: 30237992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for osteoporosis.
    Feurer E; Chapurlat R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):385-95. PubMed ID: 24995794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bones, heart and the new anabolic agent romosozumab.
    Pazianas M
    Postgrad Med J; 2019 Oct; 95(1128):521-523. PubMed ID: 31422376
    [No Abstract]   [Full Text] [Related]  

  • 13. Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.
    Fontalis A; Kenanidis E; Kotronias RA; Papachristou A; Anagnostis P; Potoupnis M; Tsiridis E
    Expert Opin Pharmacother; 2019 Jun; 20(9):1123-1134. PubMed ID: 30958709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Frontiers in Osteoporosis Therapy.
    Cheng C; Wentworth K; Shoback DM
    Annu Rev Med; 2020 Jan; 71():277-288. PubMed ID: 31509477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental drug may change the treatment of osteoporosis. Romosozumab appears to increase bone mineral density and help rebuild the skeleton at the same time.
    Duke Med Health News; 2014 Apr; 20(4):7. PubMed ID: 25195210
    [No Abstract]   [Full Text] [Related]  

  • 16. Perspectives on osteoporosis therapies.
    Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
    J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel anti-osteoporotic drugs on the horizon].
    Knauerhase A; Willenberg HS
    Z Rheumatol; 2016 Jun; 75(5):466-70. PubMed ID: 27256100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.
    Prather C; Adams E; Zentgraf W
    Am J Health Syst Pharm; 2020 Nov; 77(23):1949-1956. PubMed ID: 32880646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.